Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3915
Source ID: NCT01467323
Associated Drug: Biphasic Insulin Aspart
Title: Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2
Interventions: DRUG: biphasic insulin aspart|DRUG: biphasic human insulin
Outcome Measures: Primary: HbA1c (glycosylated haemoglobin A1c) | Secondary: 8-point blood glucose profiles|Incidence of hypoglycaemic episodes|Occurrence of adverse events
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 303
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 1998-04
Completion Date: 1998-09
Results First Posted:
Last Update Posted: 2017-01-04
Locations: Novo Nordisk Investigational Site, Graz, 8036, Austria|Novo Nordisk Investigational Site, Wien, A 1080, Austria|Novo Nordisk Investigational Site, Anklam, 17389, Germany|Novo Nordisk Investigational Site, Berlin, 10559, Germany|Novo Nordisk Investigational Site, Berlin, 14089, Germany|Novo Nordisk Investigational Site, Cottbus, 03048, Germany|Novo Nordisk Investigational Site, Erkner, 15537, Germany|Novo Nordisk Investigational Site, Hamburg, 20251, Germany|Novo Nordisk Investigational Site, Jena, 07743, Germany|Novo Nordisk Investigational Site, Leipzig, 04177, Germany|Novo Nordisk Investigational Site, München, 80804, Germany|Novo Nordisk Investigational Site, Neunkirchen, 66538, Germany|Novo Nordisk Investigational Site, Quakenbrück, 49610, Germany|Novo Nordisk Investigational Site, Rostock, 18057, Germany|Novo Nordisk Investigational Site, Saarlouis, 66740, Germany|Novo Nordisk Investigational Site, Schwedt, 16303, Germany|Novo Nordisk Investigational Site, Ulm, 89081, Germany|Novo Nordisk Investigational Site, Würzburg, 97080, Germany|Novo Nordisk Investigational Site, Cork, Ireland|Novo Nordisk Investigational Site, Dublin 9, Ireland|Novo Nordisk Investigational Site, Dublin, DUBLIN 8, Ireland|Novo Nordisk Investigational Site, Bern, 3010, Switzerland|Novo Nordisk Investigational Site, Ayr, KA6 6DX, United Kingdom|Novo Nordisk Investigational Site, Bath, BA1 3NG, United Kingdom|Novo Nordisk Investigational Site, Birmingham, B9 5SS, United Kingdom|Novo Nordisk Investigational Site, Blackburn, BB3 3LR, United Kingdom|Novo Nordisk Investigational Site, Bolton, BL1 4QS, United Kingdom|Novo Nordisk Investigational Site, Bristol, BS2 8HW, United Kingdom|Novo Nordisk Investigational Site, Kettering, NN16 8UZ, United Kingdom|Novo Nordisk Investigational Site, Leicester, LE1 5WW, United Kingdom|Novo Nordisk Investigational Site, Livingstone, EH54 6PP, United Kingdom|Novo Nordisk Investigational Site, Newcastle, NE7 7DN, United Kingdom|Novo Nordisk Investigational Site, Northampton, NN1 5BD, United Kingdom|Novo Nordisk Investigational Site, Nottingham, NG7 2UH, United Kingdom|Novo Nordisk Investigational Site, Paisley, PA2 9PL, United Kingdom|Novo Nordisk Investigational Site, Watford, WD18 0HB, United Kingdom|Novo Nordisk Investigational Site, Whiston, L35 5DR, United Kingdom
URL: https://clinicaltrials.gov/show/NCT01467323

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress